The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1243
September 11, 2006
View Complete Issue         Table of Contents 2019 
Darunavir (Prezista) for HIV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Darunavir (Prezista) for HIV Infection
September 11, 2006 (Issue: 1243)
Darunavir (Prezista - Tibotec), a new protease inhibitor, has received accelerated approval from the FDA for use in combination therapy of human-immunodeficiency virus (HIV) infection in previously treated adults. It is coadministered with low-dose...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Darunavir (Prezista) for HIV Infection
Article code: 1243b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.